Mainstream

Karyopharm outlines $1B peak U.S. revenue opportunity in myelofibrosis with pivotal Phase III data expected by March 2026

Karyopharm outlines $1B peak U.S. revenue opportunity in myelofibrosis with pivotal Phase III data expected by March 2026

Post ContentkptiRead More

You might also be interested in reading Earnings Snapshot: Analog Devices tops FQ1 estimates; initiates FQ2 outlook.

August 11, 2025
In Mainstream